June 05, 2024
2 min watch
Save
VIDEO: Phase 2 data focus on pan-VEGF blockers, tyrosine kinase inhibitors in AMD
SEATTLE — In this video from the ARVO meeting, Jay Chhablani, MD, discusses data on pan-VEGF blockers and tyrosine kinase inhibitors for age-related macular degeneration.
In poster presentations, EyePoint Pharmaceuticals discussed its extended delivery systems, while Ocular Therapeutix presented data on tyrosine kinase inhibitors.
“Some of the phase 2 trial data on pan-VEGF blockers, as well as tyrosine kinase inhibitors, were presented [at the ARVO meeting],” Chhablani, professor of ophthalmology at University of Pittsburgh School of Medicine, said. “We are really excited to see how these phase 2 data show up in phase 3.”
Published by:
Sources/Disclosures
Collapse
Source:
Healio Interviews
Disclosures:
Chhablani reports consulting for EyePoint Pharmaceuticals.
Read more about